期刊文献+

两种剂量GM1注射液治疗急性脑梗死的临床研究

The Observation of Clinical Effects of Two Different Dosage of GM1 in Patients with Acute Cerebral Infarction
原文传递
导出
摘要 目的:观察不同剂量神经节苷脂(GM1)对急性脑梗死患者神经功能恢复的治疗效果。方法:120例急性脑梗死患者随机分为大剂量GM1组(n=40)、小剂量GM1组(n=40)和安慰剂组(n=40)。在治疗前1d、治疗后14d时分别对患者神经功能评价。结果:治疗后,各组的NDS评分下降、日常生活活动能力(Barthelindex,BI)评分提高;与安慰剂组相比,GM治疗组患者神经功能恢复水平明显提高(P<0.05);GM治疗组组间比较,大剂量GM1组治疗效果好于小剂量GM1组(P<0.05)。结论:GM1能够促进急性脑梗死损伤后神经功能的恢复,疗效呈剂量依赖性。 Objective :To observe the effects of different dosage of Gm1 in treating acute cerebral infarction. Methods :One hundred and twenty cases were randomly divided in three groups :the first group with high dosage of GM1 ,the second with low dose of GM1 ,the third with placebo. The neurological impairment score and curative effect were evaluated at the day before treatment and the 14th day after treatment. Results :There were significant differences in neurological impairment score in the three groups. The NDS grades reduced and the grades of BI rised significantly. The treatment effect of GM1 was more obvious than the placebo therapy. In addition,the treatment effect of high dosage of GM1 was more significant than the low dose GM1 group. Conclusion :GM1 improves the recovery of neurological function of the patients. The treatment effect of high dose GM1 (100 mg/d) is better than the low dose GM1 (40 mg/d), the medical effects rely on the dosage.
出处 《医药世界》 2009年第9期487-489,共3页 Medicine World
关键词 急性病 脑梗塞/药物疗法 G(M1)神经节苷脂/治疗应用 人类 Acute Disease Brain Infarction/drug therapy G(M1) Ganglioside/therapeutic use Humans
  • 相关文献

参考文献3

二级参考文献23

  • 1毛捷.神经节苷酯对脑缺血再灌注损伤谷氨酸、天门冬氨酸含量的影响[J].河北医学,2004,10(10):909-913. 被引量:1
  • 2Vukelio Z, Kalanj-Bogner S, Froesch M, et al. Human glio-sarcoma-associated ganglioside composition is complex and distinctive as evidenced by high-performance mass spectrometric determination and structural characterization. Glycobiology. Zamfir AD, 2007, 17 : 504 ~515.
  • 3She JQ, Wang M, Ruan DY, et al. Effect of ganglioside on synaptic plasticity of hippocampus in lead-exposed rats in vivo. Brain Res, 2005, 1060 : 162 -169.
  • 4Vyas AA, Patel HV, Fromholt SE, et al. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein( MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci USA, 2002, 99 : 8412 -8417.
  • 5Chen N, Furuya S, Higashi H, et al. Ganglioside/calmodulin kinase II signal inducing cdc42-mediated neuronal actin reorganization. Neuroscience, 2003, 120 : 163- 176.
  • 6Chen N, Funuya S, Higashi H, et al. Extracellular carbohy- drate-signal triggering cAMP-dependent protein kinase- dependent neuronal actin-reorgnization. Neuroscience, 2003, 122 : 985 -995.
  • 7Higashi H, Chen N. Ganglioside/protein kinase signals trig-gering cytoskeletal actin reorganization. Glycoconjugate J, 2004,20 : 49 - 58.
  • 8Matsuzaki K, Noguch T, Wakabayashi M, et al. Inhibitors of amyloid beta-protein aggregation mediated by GM1- containing raft-like membranes. Biochim Biophys Acta, 2007, 1768 : 122- 130.
  • 9Yamamoto N, Yokoseki T, Shubata M, et al. Suppression of Aβ deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. Biochem Biophys Res Commun, 2005, 335 : 45 -47.
  • 10Kimuva N, Yanagisawa K. Endosomal accumulation of GM1 ganglioside-bound amyloid beta-protein in neurons of aged monkey brains. Neuroreport, 2007, 18 : 1669 - 1673.

共引文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部